BeyondSpring Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on cancer therapies, including Plinabulin development, financial results and capital structure. Its Form 10-K and Form 8-K disclosures cover audited consolidated financial statements, quarterly and annual operating results, clinical-program updates, and risk and business information tied to oncology development.
Current reports also record material agreements, registered offerings of ordinary shares, SEED Therapeutics financing and ownership disclosures, and shareholder-vote results from annual meetings. These filings describe governance actions, securities issuances, registration-statement use and other material events affecting BeyondSpring’s public-company reporting.
Decheng Capital and related funds disclosed initial beneficial ownership in BeyondSpring Inc. (BYSI). Three Decheng-managed funds report indirect holdings of 1,979,072, 1,903,579 and 1,000,000 ordinary shares respectively. The filings indicate indirect ownership through general partner entities and identify Dr. Xiangmin Cui as manager with disclaimers of ownership except for pecuniary interest. No derivative securities are reported.